Author: Vikas Kumar
04 March 2022
Plasma Fractionation market is expected to exceed the market valuation of more than ~US$ 43 billion by 2027 expanding at a reasonable CAGR of around ~6% during the forecast period (2021-2027). Plasma fractionation is the downstream processing of plasma that has been harvested by donors. It breaks plasma into individual proteins, or plasma fractions. This is different from whole blood fractionation, which means taking whole blood and breaking it into its four main parts. Over time, the scope of plasma fraction use has expanded and there are now over 20 different proteins that are of interest to the healthcare industry and therapeutics/biologics. In 2018, the number of plasma fractionation plants in the Asia-Pacific region stood at 39 while there were 21 plants in Europe.
For a detailed analysis of the Plasma Fractionation Market browse throughhttps://univdatos.com/report/plasma-fractionation-market/
Immunoglobulins are used as first-line therapy for various neurologic, immunologic, and hematologic conditions. The most common use of immunoglobulin therapy is for the treatment of primary immune deficiencies and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Intravenous immunoglobulin (IVIg) is also being considered for a range of neurological diseases, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome. In the last decade, the diagnosis rate of various immunological diseases has increased due to technological advancements. In addition, growing genetic research for characterizing and diagnosing immunodeficiency will increase the clinical need for immunoglobulins due to the increased number of diagnosed patients. Hemophilia or hematology disorders form one of the major application areas of plasma fractionation products. Hemophilia is a hereditary bleeding disorder characterized by impaired blood coagulation due to deficiencies in the production or function of coagulation factor VIII. According to the World Federation of Hemophilia, the number of hemophilia patients worldwide was 167,110 in 2011, which increased by 25.9% to 210,454 in 2018. Only 30% of patients are actually diagnosed with hemophilia, and 25% of them receive treatment. The rest of the people with hemophilia remain undiagnosed, and nearly 75% of patients receive inadequate treatment or no treatment at all.
For a detailed analysis of the market drivers in Plasma Fractionation Market browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18131
The pandemic of coronavirus disease 2019 (COVID-19) has caused over millions of confirmed cases and hundreds of thousands of deaths worldwide as reported by the World Health Organization (WHO) and has shown tremendous impacts on globe health and economics. The Plasma Fractionation Market was also impacted during the pandemic because of involuntary medical services were stopped at the time. However, the Plasma Fractionation Market is expected to bounce back after the end of the pandemic.
Based on Product, the Plasma Fractionation Market is segmented into Immunoglobulins, Coagulation Factor Concentrates, Albumin, Protease Inhibitors, and Others. Plasma-derived immunoglobulins are giving a new narrative to healthcare across a wide range of autoimmune inflammatory diseases. Clinically relevant antibody specific immunoglobulins include anti-D (anti-Rho), and antiHAV, anti-HBs, anti-tetanus, anti-varicella/herpes zoster and anti-rabies immunoglobulins.
Based on Application, the Plasma Fractionation Market is segmented into Neurology, Immunology, Hematology, Critical care, Pulmonology, and Others. The largest share of this segment is mainly attributed to the surging neurological disorders that require plasma fractionation products and increasing research studies on plasma-derived products for neurological diseases. Additionally, the response of IVIg in a shorter period than steroids or oral immunosuppressants and its effectiveness in a number of disorders of the peripheral and central nervous systems is also a driving factor.
For a detailed analysis of the End-User in the Plasma Fractionation Market browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=18131
Based on End-User, the Plasma Fractionation Market is segmented into Hospitals & Clinics, Clinical Research Laboratories, and Others. The growing need for therapies for immunodeficiency disorders, growing number of hospitals & healthcare expenditure, and rising consumption of plasma-derived products by hospitals & clinics are some of the major factors driving the growth of this segment.
Additionally, the report provides detailed initiatives that are being taken in the field of Plasma Fractionation globally. The report provides a detailed analysis of regions including North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), Rest of World. North America dominated the market in 2020, with XX% share.
Baxter International Inc., Bio product laboratory, Biotest AG, CSL Ltd., Grifols SA, Kedrion S.P.A (Kedrion Biopharma Inc.), LFB S. A., Octapharma AG, Sanquin Blood Supply Foundation, and Takeda Pharmaceutical Company Limited are some of the prominent players operating in the Plasma Fractionation market. Several M&As along with partnerships have been undertaken by these players to make Plasma Fractionation as cost-effective and as widely available as possible.
Request for Sample of the report browse throughhttps://univdatos.com/get-a-free-sample-form-php/?product_id=18131
Plasma Fractionation Market Segmentation
Market Insight, by Product
Market Insight, by Application
Market Insight, by End-User
Market Insight, by Region
Top Company Profiles
Get a call back
